
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
January 10th, 2025
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
January 10th, 2025
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18th, 2024
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
September 17th, 2024
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
July 29th, 2024
Applied DNA and Alphazyme Conclude Linea™ RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea™ IVT Platform Economics
June 20th, 2024
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
June 5th, 2024
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
May 13th, 2024
APDN Awarded Contract by HDT Bio For Rapid Vaccine Development Program
April 25th, 2024
Applied DNA, Alphazyme Agreement for Scale-Up Linea™ RNAP
March 18th, 2024